CIK cells

Phase 2Small molecule

TTianjin Medical University Cancer Institute and Hospital

CIK cells is one of 149 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

148

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Myelodysplastic SyndromesActive, not recruiting

Stem Cell TransplantCompleted

Myeloproliferative DisorderActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

Myelodysplastic SyndromesPhase 1/Phase 2

Active, not recruiting

Stem Cell TransplantPreclinical

Completed

Myeloproliferative DisorderPhase 2

Active, not recruiting

Competition

Competitive Landscape

686 competitors in Lung Cancer

#DrugCompanyPhaseTrials

CIK cells

TTianjin Medical University Cancer Institute and Hospital

Phase 2

1 2

Tecentriq

Roche

Preclinical

9 3

Libtayo

Regeneron

Preclinical

3 4

Talzenna

Pfizer

Preclinical

2 5

Folvite

Xylocaine

2 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

5 8

Paclitaxel and Carboplatin

Bristol-Myers Squibb

Preclinical

2 9

Rilotumumab

Amgen

Preclinical

2 10

Acupan

YYonsei University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Lung Cancer

NCT04836728

Clinical

Trials by Indication[1]

Hematologic Malignancies1 trial

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

Completed·SSally Arai·Phase 1·NCT00477035·22 enrolled

Renal Cell Carcinoma1 trial

Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT03987698·90 enrolled

Myelodysplastic Syndromes1 trial

CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.

Unknown status·PPeter Bader·Phase 1/2·NCT02752243·32 enrolled

Myeloproliferative Disorder1 trial

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

Completed·EEverett Meyer·Phase 2·NCT01392989·44 enrolled

Lung Cancer1 trial

Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer

Active, not recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04836728·156 enrolled

1 more indication

Stem Cell Transplant1 trial

An Investigator's Initiated Clinical Study to Evaluate the Safety of Cytokine-Induced-Killer Cells During Early Transplant Period of Autologous Hematopoietic Stem Cell Transplant Recipients.

Completed·LLucasBio·Preclinical·NCT07692607·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for CIK cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CIK cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CIK cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tianjin Medical University Cancer Institute and Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTianjin Medical University Cancer Institute and Hospital

CIK cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Hematologic Malignancies1 trial

Renal Cell Carcinoma1 trial

Myelodysplastic Syndromes1 trial

Myeloproliferative Disorder1 trial

Lung Cancer1 trial

Stem Cell Transplant1 trial

References

Drug Info

Quick Facts

Related News